<!doctype html>
<html lang="es">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>Spanish Daily – Dec 9, 2025</title>
<meta name="color-scheme" content="light dark" />
<style>
  :root { --maxw: 800px; }
  html { -webkit-text-size-adjust: 100%; }
  body { margin: 0; padding: 0; font-family: system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial,sans-serif,Apple Color Emoji,Segoe UI Emoji; line-height: 1.6; font-size: 18px; }
  header, main, footer { max-width: var(--maxw); margin: 0 auto; padding: 16px; }
  header { padding-top: 20px; }
  h1 { font-size: 1.4rem; margin: 0 0 8px; }
  .subtle { opacity: 0.72; font-size: 0.95rem; }
  .card { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 14px; margin: 12px 0; }
  .tip-word { all: unset; display: inline; position: relative; cursor: pointer;
    text-decoration: underline dotted; text-underline-offset: 3px;
    padding: 0 .1em; border-radius: .35em; background: rgba(255,235,59,.28); }
  .tooltip { position: fixed; padding: .48rem .6rem; background: rgba(0,0,0,.88); color: #fff;
    border-radius: .55rem; font-size: .95rem; line-height: 1.3; max-width: min(90vw, 26rem);
    z-index: 9999; box-shadow: 0 6px 18px rgba(0,0,0,.18); }
  .content { white-space: pre-line; }
  .card { margin-bottom: 1.5em; line-height: 1.6; }
  strong { display: inline-block; margin-top: .35em; }
  details { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 12px; }
  details + details, details + .card { margin-top: 12px; }
  summary { cursor: pointer; font-weight: 600; }
  summary::marker { content: ""; }
  summary::after { content: " ▸"; }
  details[open] summary::after { content: " ▾"; }
  .debug { position: fixed; bottom: 8px; right: 8px; font-size: 12px; opacity: .6; }
</style>
</head>
<body>
  <header>
    <h1>Spanish Daily</h1>
    <div class="subtle">Toca una palabra subrayada para ver la traducción. Toca fuera para cerrar.</div>
  </header>

  <main>
    <!-- Spanish first -->
    <section class="card content">
STORY

El <span title="management">manejo</span> de la <span title="type 2 diabetes">diabetes tipo 2</span> ahora <span title="uses">utiliza</span> un <span title="cardio-renal-metabolic approach">enfoque cardio-renal-metabólico</span> (CKM). Este <span title="plan cares for">plan atiende</span> el <span title="heart">corazón</span>, los <span title="kidneys">riñones</span>, el <span title="weight">peso</span> y la <span title="blood glucose">glucosa</span> <span title="at the same time">al mismo tiempo</span>. Los <span title="ADA Standards of Care">Estándares de Cuidado de la ADA</span> ahora <span title="prioritize">priorizan</span> los <span title="GLP-1 receptor agonists">agonistas del receptor GLP-1</span>, los <span title="dual GIP/GLP-1 agonists">agonistas duales GIP/GLP-1</span> y los <span title="SGLT2 inhibitors">inhibidores de SGLT2</span> <span title="for people with">para personas con</span> obesidad, <span title="atherosclerotic cardiovascular disease">enfermedad cardiovascular aterosclerótica</span> (ASCVD), <span title="heart failure">insuficiencia cardíaca</span> o <span title="chronic kidney disease">enfermedad renal crónica</span> (ERC).

1) <span title="In people with">En personas con</span> obesidad (IMC ≥30 kg/m² o ≥27 <span title="with complications">con complicaciones</span>), <span title="use">use</span> GLP-1RA o tirzepatida <span title="early / at an early stage">de manera temprana</span>, <span title="even at the time of diagnosis">incluso al momento del diagnóstico</span>. Estos <span title="medications">medicamentos</span> <span title="achieve">logran</span> una <span title="significant weight loss">pérdida de peso significativa</span> y una <span title="reduction of HbA1c">reducción de HbA1c</span> (<span title="shown in">demostrado en</span> los <span title="studies">estudios</span> SURMOUNT-1 y SURPASS-2). <span title="Choose according to">Elija según</span> el <span title="cost">costo</span> y el <span title="access">acceso</span>.

2) <span title="In people with">En personas con</span> ASCVD o <span title="very high cardiovascular risk">riesgo cardiovascular muy alto</span>, <span title="use">use</span> GLP-1RA <span title="with proven reduction of">con reducción comprobada de</span> <span title="major cardiovascular events">eventos cardiovasculares mayores</span> (semaglutida, dulaglutida, liraglutida). El <span title="SURPASS-CVOT study">estudio SURPASS-CVOT</span> <span title="will show more about">mostrará más sobre</span> tirzepatida.

3) <span title="In CKD">En ERC</span> (<span title="low eGFR">bajo eGFR</span> y/o <span title="albuminuria">albuminuria</span>), los <span title="SGLT2 inhibitors">inhibidores de SGLT2</span> (empagliflozina, dapagliflozina, canagliflozina) <span title="are a key therapy">son una terapia clave</span> <span title="for organ protection">para la protección de órganos</span>, <span title="even if">incluso si</span> la HbA1c <span title="is controlled">está controlada</span>. <span title="Studies">Estudios</span>: EMPA-REG, CANVAS, CREDENCE, DAPA-CKD, EMPA-KIDNEY.

4) <span title="In heart failure">En insuficiencia cardíaca</span> (<span title="reduced or preserved ejection fraction">fracción de eyección reducida o preservada</span>), los <span title="SGLT2 inhibitors">inhibidores de SGLT2</span> <span title="reduce">disminuyen</span> la <span title="hospitalization">hospitalización</span> y la <span title="cardiovascular death">muerte cardiovascular</span> (<span title="studies">estudios</span> DAPA-HF, EMPEROR).

5) <span title="You can combine">Puede combinar</span> <span title="SGLT2 inhibitors">inhibidores de SGLT2</span> <span title="with">con</span> GLP-1RA o tirzepatida <span title="in patients with">en pacientes con</span> <span title="high CKM risk">alto riesgo CKM</span>. La <span title="metformin">metformina</span> <span title="is still useful">sigue siendo útil</span> <span title="if the patient tolerates it">si el paciente la tolera</span>.

<span title="Main point">Punto principal</span>: <span title="start">inicie</span> <span title="SGLT2 inhibitors">inhibidores de SGLT2</span> y <span title="incretin-based agents">agentes basados en incretinas</span> <span title="early / at an early stage">de manera temprana</span> <span title="to protect organs">para proteger los órganos</span>, <span title="not just for">no solo para</span> el <span title="stepwise control of HbA1c">control escalonado de la HbA1c</span>.

---
DIALOGUE

Narrator: <span title="Today we talk about">Hoy hablamos sobre</span> <span title="new ways to treat">nuevas formas de tratar</span> la <span title="type 2 diabetes">diabetes tipo 2</span>.
Physician: Hola. <span title="How do you feel today?">¿Cómo se siente hoy?</span>
Patient: <span title="I feel fine">Me siento bien</span>, pero <span title="I'm worried about">me preocupa</span> mi <span title="diabetes">diabetes</span>.
Physician: <span title="I want to help you with">Quiero ayudarle con</span> su <span title="heart">corazón</span>, sus <span title="kidneys">riñones</span> y su <span title="weight">peso</span>. <span title="Not just with">No solo con</span> su <span title="blood sugar">azúcar en la sangre</span>.
Patient: <span title="Why are we also talking about">¿Por qué hablamos también de</span> mi <span title="heart">corazón</span> y mis <span title="kidneys">riñones</span>?
Physician: La <span title="diabetes can damage">diabetes puede dañar</span> su <span title="heart">corazón</span> y sus <span title="kidneys">riñones</span> <span title="over time">con el tiempo</span>.
Patient: Oh, <span title="I didn't know that">no lo sabía</span>. <span title="Can the new medications help?">¿Los medicamentos nuevos pueden ayudar?</span>
Physician: Sí. <span title="We use">Usamos</span> <span title="new medications called">medicamentos nuevos llamados</span> <span title="GLP-1 agonists">agonistas de GLP-1</span> e <span title="SGLT2 inhibitors">inhibidores de SGLT2</span>.
Patient: <span title="Are they safe for me?">¿Son seguros para mí?</span>
Physician: <span title="They can protect">Pueden proteger</span> su <span title="heart">corazón</span> y sus <span title="kidneys">riñones</span>. <span title="They also help">También ayudan</span> <span title="to lose weight">a bajar de peso</span> <span title="if you have obesity">si tiene obesidad</span>.
Patient: <span title="Will I take them">¿Los tomaré</span> <span title="together with my current pills">junto con mis pastillas actuales</span>?
Physician: <span title="Maybe">Tal vez</span>. <span title="We can use">Podemos usar</span> estos <span title="new medications">medicamentos nuevos</span> <span title="alone or combined">solos o combinados</span>. La <span title="metformin">metformina</span> <span title="is still good">sigue siendo buena</span> <span title="if you can take it">si la puede tomar</span>.
Patient: <span title="Is it very expensive?">¿Es muy caro?</span>
Physician: <span title="We will check">Revisaremos</span> su <span title="insurance">seguro</span> y <span title="we will talk about">hablaremos sobre</span> el <span title="cost">costo</span>. <span title="You can choose">Usted puede elegir</span> el <span title="best plan">mejor plan</span>.
Patient: <span title="Thank you for explaining">Gracias por explicarme</span>. <span title="I want to protect my organs">Quiero proteger mis órganos</span>.

    </section>

    <!-- English below -->

    <details open class="card content">
      <summary>INGLÉS</summary>
STORY

Type 2 diabetes care now uses a cardio-kidney-metabolic (CKM) plan. This plan cares for heart, kidney, weight, and glucose at the same time. The ADA Standards of Care now put GLP-1 receptor agonists, dual GIP/GLP-1 agonists, and SGLT2 inhibitors first for people with obesity, ASCVD, heart failure, or CKD.

1) In people with obesity (BMI ≥30 kg/m² or ≥27 with complications), use GLP-1RA or tirzepatide early, even at diagnosis. These give strong weight loss and HbA1c drop (shown in SURMOUNT-1 and SURPASS-2). Choose based on cost and access.

2) In people with ASCVD or very high CV risk, use GLP-1RA with proven MACE reduction (semaglutide, dulaglutide, liraglutide). SURPASS-CVOT will show more about tirzepatide.

3) In CKD (low eGFR and/or albuminuria), SGLT2i (empagliflozin, dapagliflozin, canagliflozin) are key organ-protective therapy, even if HbA1c is okay. Trials: EMPA-REG, CANVAS, CREDENCE, DAPA-CKD, EMPA-KIDNEY.

4) In heart failure (HFrEF or HFpEF), SGLT2i lower hospitalization and CV death (DAPA-HF, EMPEROR trials).

5) You can combine SGLT2i with GLP-1RA or tirzepatide in high CKM risk. Metformin is still useful if the patient can take it.

Main point: start SGLT2i and incretin-based agents early for organ protection, not only for stepwise HbA1c control.

---
DIALOGUE

Narrator: Today, we talk about new ways to treat type 2 diabetes.
Physician: Hello. How are you feeling today?
Patient: I feel okay, but I worry about my diabetes.
Physician: I want to help your heart, kidneys, and weight. Not just your blood sugar.
Patient: Why do we talk about my heart and kidneys too?
Physician: Diabetes can hurt your heart and kidneys over time.
Patient: Oh, I did not know that. Can new medicine help?
Physician: Yes. We use new drugs called GLP-1 agonists and SGLT2 inhibitors.
Patient: Are these safe for me?
Physician: They can protect your heart and kidneys. They also help with weight loss if you have obesity.
Patient: Will I take them with my current pills?
Physician: Maybe. We can use these new drugs alone or together. Metformin is still good if you can take it.
Patient: Is it very expensive?
Physician: We will check your insurance and talk about cost. You can choose the best plan.
Patient: Thank you for explaining. I want to protect my organs.
    </details>
  </main>

  <footer class="subtle">
    <div>© Dec 9, 2025 · Mezra.AI · Practica todos los días.</div>
  </footer>

  <div class="debug">EN: found</div>

  <!-- NEW: light cache-busting helper -->
  <script>
  (function() {
    // 1. Get the version tag from the URL, if present (?v=SHA...)
    var params = new URLSearchParams(window.location.search);
    var version = params.get('v');

    // 2. Read the debug indicator already inside your page
    var debug = document.querySelector('.debug');
    var debugText = debug ? debug.textContent.trim() : '';

    // 3. Heuristic: if version is missing or debug looks suspicious, force a one-time reload
    var isLikelyStale =
      !version ||
      debugText === '' ||
      debugText.indexOf('placeholder') !== -1 ||
      debugText.indexOf('not found') !== -1 ||
      debugText.length < 3;

    if (isLikelyStale) {
      if (!params.get('forceReload')) {
        params.set('forceReload', '1');
        var newUrl = window.location.pathname + '?' + params.toString();
        window.location.replace(newUrl);
      }
    }
  })();
  </script>

  <!-- Existing tooltip behavior -->
  <script>
  (function () {
    document.querySelectorAll('.content').forEach(function(container) {
      container.querySelectorAll('span[title]').forEach(function(span) {
        var text = span.textContent;
        var tip  = span.getAttribute('title');
        var btn  = document.createElement('button');
        btn.className = 'tip-word'; btn.type = 'button';
        btn.textContent = text; btn.setAttribute('data-tip', tip);
        span.replaceWith(btn);
      });
    });

    var openTip = null;
    function closeTip(){ if(openTip){ openTip.remove(); openTip = null; } }
    function showTip(target){
      closeTip();
      var tipText = target.getAttribute('data-tip') || '';
      if(!tipText) return;
      var bubble = document.createElement('div');
      bubble.className = 'tooltip';
      bubble.textContent = tipText;
      document.body.appendChild(bubble);
      var r = target.getBoundingClientRect();
      var m = 8, vw = innerWidth, vh = innerHeight;
      var rect = bubble.getBoundingClientRect();
      var tw = rect.width;
      var th = rect.height;
      var left = r.left, top = r.bottom + m;
      if (left + tw + m > vw) left = Math.max(m, vw - tw - m);
      if (left < m) left = m;
      if (top + th + m > vh) top = Math.max(m, r.top - th - m);
      bubble.style.left = left + 'px';
      bubble.style.top  = top + 'px';
      openTip = bubble;
    }

    document.addEventListener('click', function(e) {
      var word = e.target.closest('.tip-word');
      if (word){ if (openTip) closeTip(); else showTip(word); e.stopPropagation(); }
      else { closeTip(); }
    });
    document.addEventListener('touchstart', function(e) {
      if (!e.target.closest('.tip-word')) closeTip();
    }, { passive: true });
    addEventListener('scroll', closeTip, { passive: true });
    addEventListener('resize', closeTip);
    document.addEventListener('keydown', function(e) { if (e.key === 'Escape') closeTip(); });
  })();
  </script>
</body>
</html>